The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer

Jeong Won Lee, Arthur Cho, Jae Hoon Lee, Mijin Yun, Jong Doo Lee, Young Tae Kim, Won Jun Kang

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.

Methods: A total of 175 patients with epithelial ovarian cancer who underwent 18 F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT was measured for all patients. Because nine patients showed low tumor-to-background uptake ratios, MTV and TLG were measured in 166 patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival.

Results: Disease progressed in 78 (44.6 %) of the 175 patients, and the 2-year disease progression-free survival rate was 57.5 %. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p < 0.05). Among these variables, tumor stage (p = 0.0006) and TLG (p = 0.008) independently correlated with disease progression-free survival on multivariate analysis. The disease progression rate was only 2.3 % in stage I-II patients with low TLG (≤100.0), compared to 80.0 % in stage III-IV patients with high TLG (>100.0).

Conclusion: Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery.

Original languageEnglish
Pages (from-to)1898-1906
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume41
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Deoxyglucose
Glycolysis
Tumor Burden
Disease-Free Survival
Disease Progression
Neoplasms
Positron Emission Tomography Computed Tomography
Ovarian epithelial cancer
Fluorodeoxyglucose F18
Residual Neoplasm
Multivariate Analysis
Survival Rate
Lymph Nodes
Carbohydrates
Neoplasm Metastasis
Antigens
Serum

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Lee, Jeong Won ; Cho, Arthur ; Lee, Jae Hoon ; Yun, Mijin ; Lee, Jong Doo ; Kim, Young Tae ; Kang, Won Jun. / The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. In: European Journal of Nuclear Medicine and Molecular Imaging. 2014 ; Vol. 41, No. 10. pp. 1898-1906.
@article{cc9cabbefa6a4b80b2801af0cb1cc6d1,
title = "The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer",
abstract = "Purpose: This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.Methods: A total of 175 patients with epithelial ovarian cancer who underwent 18 F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT was measured for all patients. Because nine patients showed low tumor-to-background uptake ratios, MTV and TLG were measured in 166 patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival.Results: Disease progressed in 78 (44.6 {\%}) of the 175 patients, and the 2-year disease progression-free survival rate was 57.5 {\%}. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p < 0.05). Among these variables, tumor stage (p = 0.0006) and TLG (p = 0.008) independently correlated with disease progression-free survival on multivariate analysis. The disease progression rate was only 2.3 {\%} in stage I-II patients with low TLG (≤100.0), compared to 80.0 {\%} in stage III-IV patients with high TLG (>100.0).Conclusion: Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery.",
author = "Lee, {Jeong Won} and Arthur Cho and Lee, {Jae Hoon} and Mijin Yun and Lee, {Jong Doo} and Kim, {Young Tae} and Kang, {Won Jun}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00259-014-2803-x",
language = "English",
volume = "41",
pages = "1898--1906",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "10",

}

The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. / Lee, Jeong Won; Cho, Arthur; Lee, Jae Hoon; Yun, Mijin; Lee, Jong Doo; Kim, Young Tae; Kang, Won Jun.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, No. 10, 01.01.2014, p. 1898-1906.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer

AU - Lee, Jeong Won

AU - Cho, Arthur

AU - Lee, Jae Hoon

AU - Yun, Mijin

AU - Lee, Jong Doo

AU - Kim, Young Tae

AU - Kang, Won Jun

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.Methods: A total of 175 patients with epithelial ovarian cancer who underwent 18 F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT was measured for all patients. Because nine patients showed low tumor-to-background uptake ratios, MTV and TLG were measured in 166 patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival.Results: Disease progressed in 78 (44.6 %) of the 175 patients, and the 2-year disease progression-free survival rate was 57.5 %. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p < 0.05). Among these variables, tumor stage (p = 0.0006) and TLG (p = 0.008) independently correlated with disease progression-free survival on multivariate analysis. The disease progression rate was only 2.3 % in stage I-II patients with low TLG (≤100.0), compared to 80.0 % in stage III-IV patients with high TLG (>100.0).Conclusion: Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery.

AB - Purpose: This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.Methods: A total of 175 patients with epithelial ovarian cancer who underwent 18 F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT was measured for all patients. Because nine patients showed low tumor-to-background uptake ratios, MTV and TLG were measured in 166 patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival.Results: Disease progressed in 78 (44.6 %) of the 175 patients, and the 2-year disease progression-free survival rate was 57.5 %. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p < 0.05). Among these variables, tumor stage (p = 0.0006) and TLG (p = 0.008) independently correlated with disease progression-free survival on multivariate analysis. The disease progression rate was only 2.3 % in stage I-II patients with low TLG (≤100.0), compared to 80.0 % in stage III-IV patients with high TLG (>100.0).Conclusion: Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery.

UR - http://www.scopus.com/inward/record.url?scp=84930730413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930730413&partnerID=8YFLogxK

U2 - 10.1007/s00259-014-2803-x

DO - 10.1007/s00259-014-2803-x

M3 - Article

C2 - 24852188

AN - SCOPUS:84930730413

VL - 41

SP - 1898

EP - 1906

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 10

ER -